Skip To Main Content
Peter Hofland on Muck Rack

Peter Hofland

Verified
  • Executive Editor, Onco’Zine
  • Executive Editor, Journal of Antibody-drug, ADC Review
  • None, ADC Review, Onco’Zine
United States
As seen in: ADC Review, Onco’Zine
Journalist & Medical Writer/Editor - R&D/Life #Science #Biotech #Pharma. Managing Partner InPress Media Group & Sunvalley Communication

Get in touch with Peter

Contact Peter, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Novartis and Myricx Bio: Pioneering Next-Generation ADC Innovation with N-Myristoyltransferase Inhibitor Payloads

|
By Peter Hofland Verified
| ADC Review
This week Novartis announced the acquisition of Myricx Bio, a privately held UK-based biotechnology company developing a novel class of antibody-drug conjugates (ADCs) featuring N-myristoyltransferase inhibitor (NMTi) payloads.
Open in Who Shared Issue with article?

Genomic Tests Guide Chemotherapy Decisions in Advanced Prostate and Breast Cancer: Landmark Evidence from ENZAMET and OPTIMA Trials - Onco'Zine

|
By Peter Hofland Verified
| Onco’Zine Verified
Recent advances in cancer genomics have ushered in an era of personalized oncology, enabling clinicians to tailor treatment decisions based on tumor biology rather than clinical risk factors alone.
Open in Who Shared Issue with article?

Practice-Changing Advances in Early HER2-Positive Breast Cancer: ASCO 2026 and FDA Approvals Establish Trastuzumab Deruxtecan as a New Standard

|
By Peter Hofland Verified
| ADC Review
The annual meeting of the American Society of Clinical Oncology ASCO, held May 29 – June 2, 2026, in Chicago, and recent approvals by the US Food and Drug Administration (FDA) have transformed the management of early-stage HER2-positive breast cancer. Trastuzumab deruxtecan (T-DXd, Enhertu®; Daiichi Sankyo and AstraZeneca) is now established as a foundational therapy in both the neoadjuvant and adjuvant settings.
Open in Who Shared View Duplicates (2) Issue with article?
See all 155 articles